If Gradalis are playing hardball, they may want to give some real thought as to where they go from here in light of Samsung being forced to pay Apple $1B for patent infringements.
I would say the risk factor for them just got a whole lot bigger if they think they can bluff their way through the need for a licence. Certainly, any would-be investor would have to think twice about putting money into Gradalis with the possibility of legal action hanging over them if they try to commercialize a treatment without a licence from BLT.
I think the issue is now definitely just one of timing. They may be waiting until they have more cash in the bank before taking out a licence so as not to divert R&D funds at this stage of development. Who knows, but I think giving them a little nudge right now, after the pro Apple judgement, would not go astray.
BLT Price at posting:
45.0¢ Sentiment: Hold Disclosure: Held
